Aug 19, 2017
Prima BioMed Appoints Non-Executive Director to the Board
Aug 14, 2017
Prima BioMed Receives A$1.3 Million Tax Refund from French Government
Jul 18, 2017
Financial Update 2H17
Jul 15, 2017
Prima BioMed Announces Second Milestone Payment for IMP701 Program
Jul 08, 2017
Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial
Jun 28, 2017
Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares
Jun 25, 2017
Operational Update
Jun 05, 2017
ASCO Poster 2017
Jun 03, 2017
LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial
May 30, 2017
Prima BioMed Announces Formation of Clinical Advisory Board
May 16, 2017
Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
Apr 17, 2017
Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
Apr 11, 2017
Prima BioMed receives A$492,144 Tax Refund from Australian Government
Mar 15, 2017
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Mar 01, 2017
USA Patent Grants for IMP321 in Cancer
